
B2B-Licensing
Product List


2026



GL Pharma

01/08.2026





ORAL SOLIDS
Lannach

About Us

We are committed to developing and commercializing innovative medicines for the treatment of severe and chronic conditions worldwide.

As a trusted partner in healthcare, we collaborate closely with physicians, pharmacists, patients, and pharmaceutical wholesalers. As an international company, we market our products through a strong network of license partners and subsidiaries in more than 65 countries.

Core Competencies

GL Pharma was formed through the merger of the pharmaceutical companies Gerot and Lannacher and has a history spanning more than 70 years.

We develop, manufacture, and market differentiated branded medicines as well as high-quality off-patent products to support the well-being of patients in Austria and international markets.

Our **core expertise** is concentrated in three key therapeutic areas:

- Cardiovascular system
- Central nervous system
- Opioid substitution & Pain therapy

GL Pharma

Manufacturing Sites

Lannach/Graz, AT

Solid oral dosage forms are a core strength of our research and development activities at our headquarters in Lannach. We specialize in the development of technically challenging products, leveraging a broad range of innovative formulation technologies.

Vienna, AT

Our Vienna team focuses on the development of liquid dosage forms, including sterile preparations. We are driven by user-friendly, compliance-supporting solutions that improve patient experience and outcomes.

Our Approach

We continuously invest in pharmaceutical research and development to improve patients' lives every day.

Innovation is the foundation of our organic growth. Our experienced scientific teams have a strong track record and are supported by collaborations with leading partners — helping us stay at the forefront of pharmaceutical development.

GL Pharma





LIQUIDS/INJECTABLES
Vienna

Your Partner Of Choice

Markets

65
Markets

Active in more than 50 markets worldwide

Team

1.200
Employees

1.200 employees in 15 countries

Revenue

350 M€
500 M€

350 M€ GL Pharma
500 M€ group revenue
incl. Genericon Pharma

Production/Volume

4,5 bn

4,5 bn defined single doses

MAs

3.000
Approved
MAs

3.000 approved marketing authorizations

GL Pharma

Source: GL Pharma, 08/2026

You Can Find Us Here

- Headquarter - Austria
- Subsidiaries and representative offices
- Licensing and distribution partners
- Cooperation with Bausch Health



GL Pharma

Therapeutic Areas

- Cardiovascular
- Depression
- Diabetes
- Epilepsy
- Opioid Use Disorder
- Pain
- Vitamins and Minerals
- Other Therapeutic Areas

Notes:

Cardiovascular

Active Substance	Dosage Form	Form	Strength	Indication	Dossier
Acetylsalicylic Acid	gastro-resistant tablets		75 mg, 100 mg, 160 mg	Anti-thrombotic	available
	tablets		75 mg, 100 mg		
Bempedoic Acid	film-coated tablets		180 mg	Lipid Modi-fication	Q1 2027
Bempedoic Acid + Ezetimibe	film-coated tablets		180 mg + 10 mg	Lipid Modi-fication	Q4 2027
Candesartan + Chlorthalidone	tablets		8 mg + 12.5 mg, 16 mg + 12.5 mg, 32 mg + 12.5 mg, 32 mg + 25 mg	High Blood Pressure	2027
Sacubitril + Valsartan	film-coated tablets		24 mg + 26 mg, 49 mg + 51 mg, 97 mg + 103 mg	Heart Failure	Q2 2027

GL Pharma

Notes:

Depression

Active Substance	Dosage Form	Form	Strength	Dossier
Fluoxetine	film-coated tablets		20 mg, 40 mg	available
Trazodone	oral solution		10 mg/ml (120 ml)	available
Vortioxetine	film-coated tablets	/	5 mg, 10 mg, 15 mg, 20 mg	available

Notes:

Diabetes

Active Substance	Dosage Form	Form	Strength	Dossier
Dapagliflozin	film-coated tablets		5 mg, 10 mg	available
Empagliflozin	film-coated tablets		10 mg, 25 mg	available

Notes:

Epilepsy

Active Substance	Dosage Form	Form	Strength	Dossier
Brivaracetam	film-coated tablets		10 mg, 25 mg, 50 mg, 75 mg, 100 mg	available
Eslicarbazepine Acetate	tablets		200 mg, 400 mg, 600 mg, 800 mg	available
Ethosuximide	syrup		50 mg/ml (250 ml)	available
Lacosamide	film-coated tablets		50 mg, 100 mg, 150 mg, 200 mg	available
	oral solution		10 mg/ml (200 ml, 500 ml)	available
	solution for infusion		ampoules: 10 mg/ml (10 ml, 20 ml)	available
			vials: 10 mg/ml (20 ml)	
Levetiracetam	oral solution		100 mg/ml (150 ml, 300 ml)	available
	solution for injection		vials: 100 mg/ml (5 ml)	available
Perampanel	film-coated tablets		2 mg, 4 mg, 6 mg, 8 mg, 10 mg, 12 mg	available
Valproic Acid	oral solution		300 mg/ml (100 ml)	available

GL® Pharma

Notes:

Opioid Use Disorder

Active Substance	Dosage Form	Form	Strength	Dossier
Buprenorphine	sublingual tablets		1 mg, 2 mg	available
			4 mg, 6 mg, 8 mg, 12 mg, 16 mg	
Buprenorphine + Naloxone	sublingual tablets		2 mg + 0.5 mg, 4 mg + 1 mg, 8 mg + 2 mg	available
			12 mg + 3 mg	available
Levomethadone	tablets	 / /	2,5 mg, 5 mg, 10 mg, 20 mg, 30 mg	available
	conc. for oral solution		5 mg/ml (100 ml, 150 ml, 300 ml, 500 ml, 1000 ml)	available
Methadone	tablets	 / /	5 mg, 10 mg, 20 mg, 40 mg, 60 mg	available
	conc. for oral solution		10 mg/ml (100 ml, 150 ml, 300 ml, 500 ml, 1000 ml)	available

GL Pharma

Notes:

Pain

Active Substance	Dosage Form	Form	Strength	Dossier
Buprenorphine	sublingual tablets		0.2 mg, 0.4 mg	available
Esketamine	solution for injection		ampoules: 5 mg/ml (2 ml, 5 ml, 10 ml), 25 mg/ml (2 ml, 5 ml, 10 ml)	available
			vials: 5 mg/ml (5 ml, 10 ml, 20 ml), 25 mg/ml (5 ml, 10 ml, 20 ml)	
Hydromorphone	film-coated tablets		1.3 mg, 2.6 mg	available
	prolonged-release capsules		2 mg, 4 mg, 8 mg, 16 mg, 24 mg	2027
	solution for injection		ampoules: 2 mg/ml (1 ml), 10 mg/ml (1 ml, 10 ml), 20 mg/ml (1 ml), 50 mg/ml (1 ml)	available
Ketamine	solution for injection or infusion		ampoules: 10 mg/ml (2 ml, 5 ml, 10 ml), 50 mg/ml (2 ml, 5 ml, 10 ml)	available
			vials: 10 mg/ml (5 ml, 10 ml, 20 ml), 50 mg/ml (5 ml, 10 ml, 20 ml)	
Metamizole	solution for injection		ampoules: 500 mg/ml (2 ml, 5 ml)	available
Morphine	solution for injection		ampoules: 10 mg/ml (1 ml)	available
			vials: 10 mg/ml (10 ml), 20 mg/ml (10 ml)	

Notes:

Pain

Active Substance	Dosage Form	Form	Strength	Dossier
Oxycodone	film-coated tablets		5 mg, 10 mg, 20 mg	available
	prolonged-release tablets		5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg, 80 mg	available
	oral solution		1 mg/ml (100 ml, 250 ml, 300 ml)	available
			10 mg/ml (30 ml, 100 ml, 120 ml)	
	solution for injection or infusion		ampoules (or bottles): 10 mg/ml (1 ml, 2 ml)	available
Oxycodone + Naloxone	prolonged-release tablets		5 mg + 2.5 mg, 10 mg + 5 mg, 20 mg + 10 mg, 30 mg + 15 mg, 40 mg + 20 mg	available
Tapentadol	film-coated tablets		25 mg, 50 mg, 75 mg, 100 mg	available
	prolonged-release tablets		25 mg, 50 mg, 100 mg, 150 mg, 200 mg, 250 mg	
	oral solution		20 mg/ml (100 ml, 200 ml)	
Tramadol + Dexketoprofen	film-coated tablets		25 + 75 mg	under development

GL Pharma

Notes:

Vitamins and Minerals

Active Substance	Dosage Form	Form	Strength	Indication	Dossier
Folic Acid	tablets		1 mg, 5 mg	Folic Acid Deficiency	available
Fe^{2+} + Ascorbic Acid + Folic Acid	capsules		66.7 mg + 100 mg + 0.8 mg	Anemia during Pregnancy	available
Potassium Iodide	tablets		65 mg	Radiation Pro-phylaxis	available
Vitamin B_1 (B_1 = Benfotiamine)	film-coated tablets	/	50 mg, 150 mg, 300 mg	Vitamin B_1 Deficiency	available
Vitamin B_1+B_6 (B_1 = Benfotiamine)	film-coated tablets		100 mg + 100 mg	Vitamin B Deficiency	available
Vitamin B_1+B_6+B_{12} (B_1 = Benfotiamine)	film-coated tablets		40 mg + 90 mg + 0.25 mg	Vitamin B Deficiency	available
Vitamin B_{12} (Hydroxocobalamin)	solution for injection		ampoules: 1 mg/ml (1 ml)	Vitamin B_{12} Deficiency	available
Vitamin B_{12} (Cyanocobalamin)	film-coated tablets		1 mg, 2 mg	Vitamin B_{12} Deficiency	Q4 2026
Vitamin D_3	oral solution		14.400 IU/ml, 28.800 IU/ml	Vitamin D_3 Deficiency	available

GL Pharma

Notes:

Other Therapeutic Areas

Active Substance	Dosage Form	Form	Strength	Indication	Dossier
8-Methoxypsoralen	ampoules		0.02 mg/ml (5 ml)	Cutaneous T-Cell Lymphoma	available
Eszopiclone	film-coated tablets		1 mg, 2 mg, 3 mg	Insomnia	available
Metoclopramide	oral solution		1 mg/ml (150 ml)	Nausea, Emesis	available
	solution for injection or infusion		5 mg/ml (2 ml, 10 ml)		
Miglustat	capsules		100 mg	Type 1 Gaucher Disease	available
Tizanidine	tablet		2 mg, 4 mg, 6 mg	Muscle Spasms	available

Contact



Andreas Gasser

Head of Licensing & Business Development

M: +43 664 85 26 211

E: andreas.gasser@gl-pharma.at



Katharina Weitzer

Head of In-Licensing

M: +43 664 35 76 210

E: katharina.weitzer@gl-pharma.at



Michael Bartenstein

Managing Director

M: +43 664 23 07 667

E: michael.bartenstein@gl-pharma.com

GL Pharma



G.L. Pharma GmbH
Schlossplatz 1
A-8502 Lannach
E: licensing@gl-pharma.at
T: +43 3136 82 577

For more information please visit
our website **gl-pharma.com**

GL Pharma